Homocisteína plasmática, Lp(a) y marcadores de estrés oxidativo en la vasculopatía periférica del paciente con diabetes tipo 2

  1. José T. Real 1
  2. José Folgado 1
  3. Mercedes Molina Méndez 1
  4. Sergio Martínez-Hervás 1
  5. Marta Peiro 1
  6. Juan F. Ascaso 1
  1. 1 Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valencia
Revista:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168 1578-1879

Ano de publicación: 2016

Volume: 28

Número: 4

Páxinas: 188-194

Tipo: Artigo

Outras publicacións en: Clínica e investigación en arteriosclerosis

Resumo

Aim To study new risk factors for peripheral macroangiopathy (PM) in patients with diabetes, as oxidative stress (OS) and its interaction with classical risk factors: age, Lp(a), plasma homocysteine values and HbA1c. Subjects and methods We studied 204 type 2 diabetic (T2DM) patients, consecutive selected form a reference hospital and a secondary hospital form our Community (2009-2010). Design was a case (ABI < 0.89) control (ABI 0.9-1.2) study. PM was defined using ankle brachial index (ABI). Thirty nine T2DM subjects presented ABI > 1.2 and were excluded. Clinical and biological parameters were determined using standard methods. Results Comparing clinical and biological parameters obtained in both studied groups (T2DM + ABI < 0.9 vs T2DM + ABI 0.9-1.2), we found statistical significant differences in age, evolution time of diabetes, Lp(a) and plasma homocysteine values. No differences were found in OS parameters: reduced glutathione, oxidized glutathione and maloldialdehide between studied groups. Plasma homocysteine values were an independent risk factor for the presence of PM and were related to evolution time of diabetes and reduced glutathione. Conclusions We have confirmed that Lp(a) and independently plasma homocysteine values were related to PM in T2DM subjects. No association with PM and OS markers (GSH, GSSG and MDA) were found in T2DM with more than 10 years of evolution time of their disease and high prevalence of chronic complications.